Bristol-Myers Squibb Company PFD CONV 2
BMYMP · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $92 | $94 | $124 | $115 |
| - Cash | $16 | $13 | $11 | $10 |
| + Debt | $51 | $51 | $51 | $51 |
| Enterprise Value | $127 | $133 | $164 | $156 |
| Revenue | $12 | $12 | $11 | $12 |
| % Growth | -0.4% | 9.5% | -9.2% | – |
| Gross Profit | $9 | $8 | $7 | $7 |
| % Margin | 71.9% | 65.8% | 65.5% | 60.2% |
| EBITDA | $5 | $3 | $4 | $3 |
| % Margin | 37.5% | 26.8% | 40% | 20.7% |
| Net Income | $2 | $1 | $2 | $0 |
| % Margin | 18% | 10.7% | 21.9% | 0.6% |
| EPS Diluted | 1.08 | 0.64 | 1.2 | 0.035 |
| % Growth | 68.8% | -46.7% | 3,299.4% | – |
| Operating Cash Flow | $6 | $4 | $2 | $4 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $6 | $4 | $2 | $4 |